bimekizumab,adalimumab
ucb pharmaceuticals,abbvie
[' psa', 'be optimal', ' ada ']
be optimal: bkz in psa phase 3 rct
data at 52 wks 700+ completed study
acr50: 53% pbo/bkz, 54% bkz, 50% ada
pasi 100 65% pbo/bkz, 61% bkz, 48% ada
no rx progression 87% pbo/bkz, 89% bkz, 94% ada
candida infections 7% bkz, 0.7% ada abs#l02 #acr22 
MD, PhD Institute of Infection and Immunity @UofGlasgow UK. Past Co-chair of @EULAR Synovitis Study Group. CrossFit athlete and Mountains lover. Views my own.